The goal is to boost the immune system to suppress the virus before COVID-19 disease advances.

Wednesday, October 7, 2020 NIAID Clinical Trial Testing Hyperimmune Intravenous Immunoglobulin Plus Remdesivir to Treat COVID-19 Begins Transmission electron micrograph of SARS-CoV-2 virus particles isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID Today NIAID launched a new Phase 3 clinical trial in patients hospitalized with COVID-19 to determine if anti-coronavirus hIVIG―a highly concentrated solution of antibodies that neutralize SARS-CoV-2―combined with remdesivir can boost the immune system to suppress the virus before disease advances. The investigators hypothesize that giving people anti-coronavirus hIVIG at the onset of COVID-19 symptoms, before the body makes a protective immune response on its own, could augment the natural antibody response to SARS-CoV-2, thereby reducing the risk of more serious illness and death. Sponsored and funded by NIAID, the trial is called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107